The Proteomics Shared Resource provides analytical proteomics services to investigators in the VICC. Proteomics is the study of proteomes, which are the functional complements to genomes and which comprise diverse structural and catalytically functional multiprotein machines. Proteomics approaches offer new tools for the molecular analysis of cancer, the identification of therapeutic targets and mechanisms, and to identify markers for disease and therapeutic response. Analytical proteomics integrates tools for protein and peptide separations, MS analysis and bioinformatics to characterize proteomes and their component proteins. A unique feature of the Proteomics Shared Resource is the availability of all major proteomics analysis technologies, which offers exceptional flexibility in analytical approaches. It provides the following services: identification of proteins in both simple and complex multiprotein samples; analyses of protein modifications; analyses of differential protein expression and modification; development and implementation of methods to detect serum markers for tumors, therapeutic susceptibility and response; providing expertise and training in proteomics analysis and experimental design to VICC investigators; and facilitating the transition of new technology into proteomics research. Dr. Daniel C. Liebler serves as Scientific Director. A recent recruit to the VICC, he previously established a successful Proteomics Shared Resource in the Southeast Environmental Health Sciences Center and Arizona Cancer Center at the University of Arizona. The staff of the Shared Resource have specialized expertise that enable them assist investigators with coverage of a vast number of new technologies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA068485-09
Application #
6990134
Study Section
Subcommittee G - Education (NCI)
Project Start
2004-09-28
Project End
2009-08-31
Budget Start
2004-09-28
Budget End
2005-08-31
Support Year
9
Fiscal Year
2004
Total Cost
$152,505
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Bloodworth, Melissa H; Rusznak, Mark; Pfister, Connor C et al. (2018) Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology. J Allergy Clin Immunol 142:683-687.e12
Saito-Diaz, Kenyi; Benchabane, Hassina; Tiwari, Ajit et al. (2018) APC Inhibits Ligand-Independent Wnt Signaling by the Clathrin Endocytic Pathway. Dev Cell 44:566-581.e8
Cardin, Dana B; Thota, Ramya; Goff, Laura W et al. (2018) A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer. Am J Clin Oncol 41:772-776
Hormuth 2nd, David A; Weis, Jared A; Barnes, Stephanie L et al. (2018) Biophysical Modeling of In Vivo Glioma Response After Whole-Brain Radiation Therapy in a Murine Model of Brain Cancer. Int J Radiat Oncol Biol Phys 100:1270-1279
Rojas, Juan D; Lin, Fanglue; Chiang, Yun-Chen et al. (2018) Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy. Theranostics 8:141-155
Dutter, Brendan F; Ender, Anna; Sulikowski, Gary A et al. (2018) Rhodol-based thallium sensors for cellular imaging of potassium channel activity. Org Biomol Chem 16:5575-5579
Vierra, Nicholas C; Dickerson, Matthew T; Jordan, Kelli L et al. (2018) TALK-1 reduces delta-cell endoplasmic reticulum and cytoplasmic calcium levels limiting somatostatin secretion. Mol Metab 9:84-97
Schlegel, Cameron; Weis, Victoria G; Knowles, Byron C et al. (2018) Apical Membrane Alterations in Non-intestinal Organs in Microvillus Inclusion Disease. Dig Dis Sci 63:356-365
Lewis Jr, James S; Shelton, Jeremy; Kuhs, Krystle Lang et al. (2018) p16 Immunohistochemistry in Oropharyngeal Squamous Cell Carcinoma Using the E6H4 Antibody Clone: A Technical Method Study for Optimal Dilution. Head Neck Pathol 12:440-447
Werfel, Thomas A; Wang, Shan; Jackson, Meredith A et al. (2018) Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Cancer Res 78:1845-1858

Showing the most recent 10 out of 2462 publications